Drug intelligence / Profile preview

golidocitinib + anti-PD-1

Development stage: Unknown
Lead developer: Dizal Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

Golidocitinib in combination with anti-PD-1 antibodies is being investigated for the treatment of non-small cell lung cancer (NSCLC), particularly in patients who have progressed after prior anti-PD-1 therapy. Preclinical studies have shown that this combination has synergistic potential for anti-tumor effects. In clinical trials, the combination achieved a 44.3% response rate in NSCLC patients who had progressed after previous anti-PD-1 therapy.

Targets

JAK1 (Janus kinase 1)PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on golidocitinib + anti-PD-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on golidocitinib + anti-PD-1.

Explore the full profile